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Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive blood cancer. There are no immunotherapies and few
molecularly targeted therapeutics available for treatment of this malignancy. The identiﬁcation and characterization of
genes and pathways that drive T-ALL progression are critical for the development of new therapies for T-ALL. Here, we
determined that the protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3) plays a critical role in T-ALL initiation and
progression by promoting leukemia cell migration. PRL-3 is highly expressed in patient T-ALL samples at both the
mRNA and protein levels compared to normal lymphocytes. Knock-down of PRL-3 expression using short-hairpin RNA
(shRNA) in human T-ALL cell lines signiﬁcantly impeded T-ALL cell migration capacity in vitro and reduced their ability
to engraft and proliferate in vivo in xenograft mouse models. Additionally, PRL-3 overexpression in a Myc-induced
zebraﬁsh T-ALL model signiﬁcantly accelerated disease onset and shortened the time needed for cells to enter blood
circulation. Reverse-phase protein array (RPPA) and gene set enrichment analysis (GSEA) revealed that the SRC
signaling pathway is affected by PRL-3. Immunoblot analyses validated that manipulation of PRL-3 expression in T-ALL
cells affected the SRC signaling pathway, which is directly involved in cell migration, although Src was not a direct
substrate of PRL-3. More importantly, T-ALL cell growth and migration were inhibited by small molecule inhibition of
PRL-3, suggesting that PRL-3 has potential as a therapeutic target in T-ALL. Taken together, our study identiﬁes PRL-3
as an oncogenic driver in T-ALL both in vitro and in vivo and provides a strong rationale for targeted therapies that
interfere with PRL-3 function.

Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an
aggressive hematologic malignancy, representing 10–15%
of pediatric and 25% of adult ALL cases1. The treatment
of T-ALL lags behind that of B-cell ALL (B-ALL) and
other leukemia subtypes in regard to both availability of
immunotherapies and the development of molecular
targeted therapies2. Additionally, relapsed T-ALL remains
a major clinical concern, with less than 30% of children
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and 10% of adults surviving relapse, and current intensive
chemotherapy regimens for T-ALL have long-term
adverse effects in patients1,3–5. More effective and selective treatment strategies are critically needed for T-ALL.
The development of novel therapeutics requires the
identiﬁcation and characterization of targetable drivers of
T-ALL progression.
Protein phosphatases cooperate with kinases to precisely maintain appropriate protein phosphorylation and
have important roles in modulating the strength and
duration of signaling events, critical for normal cellular
functions. Abnormal protein phosphorylation is a common feature in cancer and disease. While kinase inhibitors
have achieved signiﬁcant success in clinic6, phosphatases
are underexplored as drug targets7,8, largely due to the
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misconception that phosphatases function primarily as
tumor suppressors, as well as the challenges in developing
speciﬁc phosphatase inhibitors. To date, more than 30
potentially oncogenic phosphatases have been identiﬁed,
and are being explored as drug targets in cancer therapy9.
Protein tyrosine phosphatase 4A3 (PTP4A3), also
known as phosphatase of regenerating liver 3 (PRL-3), is
an oncogenic phosphatase that has received signiﬁcant
attention as a potential therapeutic target in a variety of
cancers7,8,10. PRL-3 is highly expressed in ~80% of 151
human tumor tissue samples across 11 tumor types,
including liver, lung, colon, breast, stomach, thyroid,
pancreas, kidney, bladder, and prostate cancer10, and
PRL-3 has been extensively reported as a biomarker of
tumor progression and metastasis in breast11, colon12,13,
gastric14, brain15, and prostate16 cancers. Elevated PRL-3
correlates with reduced survival in patients with breast17,
gastric14, ovarian18, and liver19 cancers and in acute
myelogenous leukemia (AML)20,21. More importantly, the
causative role of PRL-3 in solid tumors has been functionally demonstrated by overexpression and knock-down
of PRL-3 in normal or cancer cells. For example, ectopic
expression of PRL-3 in human melanoma, breast, lung,
and colorectal cancer cells has been reported to increase
cell motility, migration, invasion, and proliferation in vitro
and to accelerate tumor formation, progression, and
metastasis in vivo22–25. Similarly, knock-down of PRL-3
expression using short-hairpin RNA (shRNA) led to
decreased cell proliferation, adhesion, migration, and
invasion in a range of solid tumors in vitro and inhibited
primary tumor proliferation and invasion in vivo in colorectal, gastric and ovarian cancers and in melanoma,
ultimately improving the prognosis and life span of
mice26–29.
Given the proven role of PRL-3 in solid tumor malignancies, efforts have been made to develop speciﬁc PRL-3
inhibitors, including JMS-05330, Compound 43 and its
analogs31, and Analog 332, all of which target the entire
PRL family (PRL-1, −2, and −3). In addition, a humanized
PRL-3 antibody has been developed that speciﬁcally targets PRL-3 over other family members10,33. These efforts
suggest that PRL-3 is a feasible therapeutic target in
cancer.
The role of PRL-3 in leukemia is less well deﬁned, and
its contribution to T-ALL progression has not been
reported. Here, we demonstrate that PRL-3 plays a role in
T-ALL development and migration both in vitro and
in vivo in mice and zebraﬁsh, and we provide a
mechanism by which PRL-3 may function as an oncogene
in ALL via modulation of the SRC signaling pathway to
promote T-ALL migration. Taken together, our study
identiﬁes a critical role of PRL-3 in T-ALL onset and
progression both in vitro and in vivo and suggests that
PRL-3 may be a targetable oncogenic driver in T-ALL.
Oncogenesis
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PRL-3 is highly expressed in T-ALL patient samples
and T-ALL cell lines
Analysis of bone marrow aspirate from T-ALL patients
showed that PRL-3 mRNA expression was signiﬁcantly
higher in primary T-ALL (n = 174) compared to healthy
donor samples (n = 72, GSE13159, p = 6.8e−10, Fig. 1a),
although there was no signiﬁcant difference found in
PRL-3 expression between patients who achieved complete remission (n = 29) versus those that relapsed (n =
11) or suffered induction failure (n = 7, GSE14615, Fig.
1b). However, the sample size was relatively small in the
latter study, and further investigation is warranted to
determine whether PRL-3 expression may be a predictor
of T-ALL treatment failure. Analysis of other PRL family
members showed that PRL-1 expression was signiﬁcantly
lower in primary T-ALL patient samples compared to
healthy bone marrow, while PRL-2 expression is signiﬁcantly higher (Supplemental Fig. 1).
Western blot showed 3 out of 8 T-ALL patient peripheral blood mononuclear cell (PBMC) samples expressed very high PRL-3, while it was detected at low levels, if
at all, in PBMCs from ﬁve healthy donors (Fig. 1c).
Additionally, PRL-3 protein was expressed at varying
levels across 14 T-ALL cell lines (Fig. 1d). Interestingly,
PRL-3 expression in the same cell line ﬂuctuated notably
across independent assays (Supplemental Fig. 2), although
we did not ﬁnd the expression level to be related to cell
density or serum deprivation. Consistent with gene
expression datasets, PRL-1 was not detected across
T-ALL cell lines, while PRL-2 protein was expressed in
most T-ALL cell lines examined (Supplemental Fig. 3).

PRL-3 knock-down in T-ALL cell lines inhibits cell
migration in vitro and engraftment in a xenograft
mouse model
In order to deﬁne the role of PRL-3 in T-ALL, we used
shRNAs to knock-down PRL-3 expression in Jurkat cells, a
T-ALL line with high endogenous PRL-3 expression. Western blot analysis of samples collected four days after lentiviral infection of shRNA constructs showed that PRL-3 was
successfully knocked-down by shRNA constructs #2 and #3
compared to scrambled (SCR) control shRNA (Fig. 2a).
Expression of the other PRLs did not increase to compensate
for PRL-3 loss (Supplemental Fig. 4A). Interestingly, despite
puromycin selection of the shRNA construct, PRL-3
expression levels recovered over time (Supplemental Fig.
4B), suggesting that cells with higher PRL-3 expression may
outcompete those with stronger knock-down.
PRL-3 knock-down did not negatively impact cell
growth (Fig. 2b), however, silencing PRL-3 expression
signiﬁcantly reduced cell migration by approximately 50%
(p < 0.02, Fig. 2c). Similarly, when we overexpressed PRL3 in Jurkat and HBP-ALL cells (Supplemental Fig. 5A), we
found no signiﬁcant difference in cell growth
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Fig. 1 PRL-3 is highly expressed in a majority of human T-ALL. a Microarray expression analysis of GSE13159 comparing bone marrow samples
from healthy donors (n = 72) and T-ALL patients (n = 174), ***p = 6.8e−10. b Analysis of GSE14615 comparing PRL-3 expression between bone
marrow samples from T-ALL patients achieving remission and patients with induction failure. NS = not signiﬁcant. Representative western blot
analysis of (c) primary patient T-ALL and PBMCs, and (d) human T-ALL cell lines, showing PRL-3 expression. The total protein loaded in each sample
was used as loading control instead of housekeeping protein, with a band of ~50 kD chosen as a representative image in the ﬁgure.

(Supplemental Fig. 5B), but signiﬁcantly enhanced
migratory capability compared to control (p ≤ 0.009,
Supplemental Fig. 5C). Together, these data suggest that
PRL-3 plays an important role in regulating cell migration, but not proliferation, in T-ALL cells in vitro.
In order to determine whether silencing PRL-3
expression in human T-ALL affects its oncogenic ability
in vivo, Jurkat cells expressing a scrambled shRNA or a
shRNA targeting PRL-3 were injected intravenously into
immune-compromised mice. At 4, 6, and 8 weeks after
transplantation, blood samples were collected and stained
with anti-human CD45 (Fig. 2d). Flow cytometry showed
no human CD45-positive cells in the circulation of mice
injected with PRL-3 knock-down Jurkat cells, while mice
injected with Jurkat expressing scrambled shRNA cells
showed increasing numbers of CD45 positive cells in the
blood each week (Fig. 2e, f). Three mice harboring
scrambled shRNA expressing T-ALL had to be euthanized before the 8-week time point due to mobility issues
likely caused by T-ALL inﬁltration into the spine or
central nervous system, while mice with PRL-3 knockdown remained healthy throughout the duration of the
study. The survival of mice xenografted with PRL-3
knock-down T-ALL cells may be due to decreased ability
of the cells to engraft and/or circulate, and further studies
are needed to differentiate between these possibilities.
Oncogenesis

PRL-3 enhances T-ALL onset in a zebraﬁsh model
The elevated expression of PRL-3 in T-ALL patient
samples and its role in promoting migration in T-ALL cell
lines suggests it may play an oncogenic role in T-ALL. We
used a zebraﬁsh Myc-induced T-ALL model34,35 to assess
the role of PRL-3 in T-ALL onset and progression. Zebraﬁsh prl-3 has 88% homology to human PRL-3 with conservation of critical domains36. One-cell stage zebraﬁsh
embryos were injected with plasmids containing rag2:Myc
with rag2:mCherry, and with or without rag2:prl-3; the rag2
promoter drives gene expression in lymphocytes. T-ALL
developed in zebraﬁsh from the thymus and expanded into
local tissues before entering the circulation. Fish were
monitored for leukemia growth by quantifying the percent
mCherry-positive cells within the body of the animal; >70%
mCherry-positive was considered leukemic. Zebraﬁsh TALL that expressed prl-3 consistently expanded from the
thymus into surrounding tissues earlier than T-ALL
expressing Myc alone (Fig. 3a), although there was no signiﬁcant difference in time to full leukemia onset between
the groups (Fig. 3b). Because the T-ALL cells were ﬂuorescently labeled, we were also able to determine the time at
which leukemia cells begin to circulate by visualizing cells
within the vasculature in the tail ﬁn (Fig. 3c, Supplemental
Videos 1 and 2). While more than half of animals with TALL in the Myc-expressing group never developed
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Fig. 2 PRL-3 knock-down inhibits cell migration and T-ALL engraftment in a xenograft mouse model. a Representative western blot analysis
ﬁgure showing PRL-3 protein expression in Jurkat T-ALL cells 4d post-infection with lentivirus carrying shRNA. Numbers represent relative expression
of PRL-3 protein, normalized to total protein loaded and compared to scrambled (SCR) control. b Cells infected with SCR or PRL-3 knock-down shRNA
were cultured in media 4 days post-infection with 5 μg/ml puromycin for 72 additional hours. Cell growth was determined by Cell Titer-Glo assay and
normalized to the readout of day 0, and shows no difference between groups. Data shown are the average of three independent experiments, done
in triplicate, NS = not signiﬁcant. c Knock-down of PRL-3 in Jurkat cell line reduced migration towards a serum stimulus more than 50%. Migration
was normalized to the cells infected by SCR shRNA, p < 0.05 compared to SCR control, *p < 0.05. d Schematic diagram of the xenotransplantation
assay. e Representative ﬂow cytometry analysis of submandibular blood sample after human CD45 staining. f Quantiﬁcation of human CD45 staining
of blood from mice at week 4,6, and 8 after transplantation. Each dot represents one mouse, the horizontal line represents the mean value, and the
standard deviation is shown, *p < 0.01 and **p < 0.001 compared to shRNA control xenografted mice.

circulating disease by >100d, more than 80% of the Myc +
prl-3 expressing T-ALLs were circulating at a median time
point of 42d, p = 0.05 (Fig. 3d).
The lymphoblasts were morphologically similar between
groups (Fig. 3e), and there was no signiﬁcant difference in
Myc expression between Myc and Myc + prl-3 T-ALL
samples (Fig. 3f). Gene expression analyses indicated that
both the rag2:Myc and rag2:Myc + rag2:prl-3 leukemias
expressed the lymphocyte speciﬁc genes rag1 and rag2 and
the T-cell genes lck and tcrB, but not B-cell related genes
igD or igM, indicating all leukemias generated were of Tcell origin. We veriﬁed that the rag2:Myc + rag2:prl-3
leukemias expressed >10-fold higher levels of PRL-3 than
the Myc control group (Fig. 3g). Interestingly, endogenous
prl-3 expression was also signiﬁcantly higher in the rag2:
myc T-ALL than normal zebraﬁsh blood cells, suggesting
that PRL-3 may be an important collaborating oncogene in
T-ALL development. Taken together, these data suggest
that PRL-3 can play an important role in T-ALL onset and
progression in vivo, likely by enhancing migration into
local tissues and contributing to the ability of the cells to
enter circulation.

Oncogenesis

PRL-3 modulates SRC pathway signaling to
promote T-ALL migration
Our in vitro and in vivo data suggest that PRL-3 functions in T-ALL progression by modulating leukemia cell
migration. To identify a mechanism by which PRL-3
might contribute to cell motility, we ﬁrst examined gene
signatures associated with PRL-3 expression in T-ALL
patient samples. T-ALL samples with high levels of PRL-3
(upper quartile) and low levels of PRL-3 (lower quartile)
were selected from GSE13159 (Fig. 1a) for Gene Set
Enrichment Analysis (GSEA), which identiﬁed 24 pathways that were signiﬁcantly different between the groups.
Although PRL-3 was not associated with genes linked to
any particular subtype of T-ALL, genes linked with SRC
kinase signaling, an embryonic stem cell signature, and
VEGF pathways were signiﬁcantly enriched in PRL-3 high
T-ALL (Fig. 4a and Supplemental Table 1). Additionally,
Reverse-Phase Protein Array (RPPA) on 422 proteins and
phospho-proteins identiﬁed ~20 proteins that showed
differential expression between PRL-3 knock-down or
PRL-3 overexpression T-ALL cell lines and the appropriate controls (Fig. 4b, c, Supplemental Tables 2,3). Top
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Fig. 3 PRL-3 enhances circulation of leukemia cells in a zebraﬁsh T-ALL model. a Representative images of transient transgenic zebraﬁsh
expressing rag2:Myc + rag2:mCherry (n = 11) or rag2:Myc + rag2:mCherry + rag2:prl-3 (n = 6) at 34 days post-fertilization (dpf). b Kaplan–Meier
analysis of time (days) percent survival (>70% of animal is mCherry-positive). c Representative rag2:Myc + rag2:mCherry + rag2:prl-3 animal, showing
circulating mCherry + leukemia cells within the tail ﬁn. d Kaplan–Meier analysis of time (days) for each T-ALL to be visualized in circulation, * p =
0.049. e Representative images of May-Gunwald Giemsa staining of blood samples from ﬁsh from each leukemia type. Scale bar = 100 μm. f Realtime
RT-PCR analysis of Myc expression between rag2:Myc + rag2:mCherry (n = 8) and rag2:Myc + rag2:mCherry + rag2:prl-3 (n = 5). Each point represents
one ﬁsh sample. NS = not signiﬁcant. g Realtime RT-PCR analysis of lymphocyte, T-cell, and B-cell speciﬁc genes. Bars are the average expression of
three samples per group.

hits in both knock-down and overexpression cells included Histone-H3, Chk2, and Src_pY527.
Both GSEA and RPPA data suggest that the SRC
pathway is associated with PRL-3 expression at both the
mRNA and protein level. Src is a non-receptor kinase that
is activated in a large fraction of cancers, where it plays a
prominent role in cell migration and metastasis37. Src
activity is negatively regulated by phosphorylation of
tyrosine 527, which is an inhibitory phosphorylation site
targeted by CSK (C-terminal Src Kinase). PRL-3 knockdown in Jurkat cells increased phosphorylation of
Src_Y527 compared to scrambled shRNA control (Fig. 5a
and Supplemental Fig. 6A), while PRL-3 overexpression
decreased phosphorylation of Y527 (Fig. 5b and supplemental Fig. 6B). Interestingly, CSK expression was
inversely correlated with PRL-3 expression (Fig. 5a, b),
consistent in previous reports that found PRL-3 downregulates CSK expression in human embryonic kidney
cells and colon cancer cells38.
The effect of PRL-3 on phosphorylation of Src_Y527
may be through a direct action of PRL-3 phosphatase
activity or through an indirect mechanism such as regulation of CSK or other proteins. We found that a phosphatase deﬁcient mutant PRL-3, PRL-3(C104S) partially
rescued the reduction of Src_Y527 phosphorylation
compared to PRL-3 wild-type expression (Fig. 5c),
Oncogenesis

suggesting that PRL-3 phosphatase activity likely plays a
role in Src regulation. Importantly, PRL-3(C104S) has
been previously shown to retain low levels of phosphatase
activity39; the artiﬁcially high levels of exogenous PRL3
(C104S) expression in the Jurkat cells may therefore
compensate for reduced phosphatase activity, leading to
incomplete rescue of the phosphorylation of Src_Y527.
Interestingly, we found that Src did not coimmunoprecipitate with Flag-tagged PRL-3 or PRL-3
(C104S), despite being found at high levels in Jurkat cell
lysate (Fig. 5e). These results indicate that Src is not a
direct substrate of PRL-3 in T-ALL and PRL-3 modulates
Src_Y527 phosphorylation by either inhibiting CSK
expression, or via an unknown protein intermediate
(Fig. 5f).

Small molecule inhibition of PRL-3 reduces Src
pathway activation and blocks T-ALL migration
T-ALL migration plays a critical role in T-ALL progression and our data show PRL-3 can directly affect the
migratory phenotype of T-ALL cells both in vitro and
in vivo. Small molecule inhibition of PRL-3 can block
solid tumor progression40, and we wanted to examine the
effects of PRL-3 inhibition in T-ALL cells. The noncompetitive small molecule PRL inhibitor, JMS-05340
signiﬁcantly reduced the viability of T-ALL cells in a dose
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Fig. 4 Src is a target of PRL-3. a GSEA analysis of T-ALL patients samples (GSE13159) comparing bone marrow with high PRL-3 expression (upper
quartile) vs low PRL-3 expression (bottom quartile), showing the normalized enrichement score (NES). Reverse-phase protein array analysis (RPPA) of
(b) PRL-3 knock-down or (c) overexpression of PRL-3 in Jurkat cells showed differential protein expression when compared to controls. Red bars show
any protein that was up or down regulated 20%, and protein names shown in red are common in both groups, and include Chk2, Histone H3, and
Src_pY527.

dependent manner (Fig. 6a), with lesser to no effects in
cell lines that did not routinely express high levels of PRL3. PRL-3 inhibition increased apoptosis in T-ALL cells
after 24 h, although this trend was not signiﬁcant across
multiple experiments (Supplemental Fig. 7A), with no
effect on cell cycle, measured by EdU uptake (Supplemental Fig. 7B). Short-term (<2 h) JMS-053 treatment
signiﬁcantly (p < 0.001) impaired the migration capability
of all PRL-3 expressing T-ALL cell lines tested, reducing
cell migration through a transwell towards a serum stimulus by 30–80% (Fig. 6b). JMS-053 treatment increased
the phosphorylation Src_Y527 (Fig. 6c), again indicating
that PRL-3 promotes cell migration by activation of Src.
Finally, we used the Src inhibitor Su6656 to treat PRL-3
overexpressing cells in combination with JMS-053, and
evaluated whether the inhibitors synergized to affect cell
migration capability. While both JMS-053 and
Su6656 signiﬁcantly decreased cell migration compared to
control, we found no signiﬁcant additive effect when both
inhibitors were used (Fig. 6d), supporting the hypothesis
that PRL-3 modulates Src signaling to promote cell
migration. Taken together, our data showed that small
molecule inhibition of PRL-3 can block T-ALL growth
and migration in vitro, likely due to Src inhibition, and
Oncogenesis

suggest that PRL-3 might be a useful target to control TALL progression.

Discussion
Compared to other types of leukemia, T-ALL is urgently
lacking immunotherapies or molecularly targeted therapies, which correlates with a worse prognosis for patients
who fail traditional chemotherapy regimens. Central
nervous system (CNS) inﬁltration by T-ALL and both
CNS and bone marrow relapse remain critical clinical
challenges, with survival rates of relapsed disease as low as
40%41. The identiﬁcation and characterization of important drivers of T-ALL progression are needed for the
design of novel, targeted therapeutics.
We found PRL-3 was highly expressed in T-ALL patient
samples and cell lines, consistent with studies reporting
PRL-3 upregulation in solid tumors42 and B-ALL43.
Importantly, we used two different animal models to
demonstrate an oncogenic role for PRL-3 in T-ALL,
which, to the best of our knowledge, is the ﬁrst in vivo
study demonstrating this ﬁnding. In zebraﬁsh, PRL-3
expression enhanced the spread of T-ALL cells from the
thymus into surrounding tissues and promoted their rapid
entry into circulation. In mouse xenograft, human T-ALL
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Fig. 5 PRL-3 modulates Src phosphorylation. a Representative western blot analysis of Src_pY527, total Src, and CSK in Jurkat cells with PRL-3
knock-down. b Western blot validation of Src pathway in PRL-3 overexpressing Jurkat cells. Cells were serum starved overnight and added to serum
containing complete media for the indicated time points. Numbers shown represent relative protein expression. c Representative western blot
validation of Src pathway in 3xFlag PRL-3 Wt and 3xFlag PRL-3 C104S mutant Jurkat cells. d Quantiﬁcation of n = 4 independent experiments
analyzing SRC_pY527, *p = 0.003. e Co-immunoprecipitation assay of Jurkat overexpressing PRL-3 substrate trapping mutants, 3xFlag PRL-3 C104S or
3xFlag PRL-3 C104D, did not pulldown Src. f Schematic of PRL-3 and modulation of Src pathway in T-ALL cells.

cells with silenced PRL-3 expression had diminished
capacity to engraft and mice remained generally
leukemia-free throughout the study. While we hypothesize the lack of T-ALL engraftment associated with PRL-3
knock-down may be attributed to a decreased ability of
the leukemia cells to migrate and home to the bone
marrow or thymus niche after xenograft, this needs to be
conﬁrmed experimentally. Given PRL-3 is established as
enhancing viability and preventing apoptosis in other
cancers44, PRL-3 might be playing additional roles in vivo
that contribute to ﬁtness of the T-ALL cells.
Overall, our data suggest that the primary role of PRL-3 in
T-ALL is to promote cell migration, similar to its role in
solid tumors. Recently, invasion and migration phenotypes
Oncogenesis

have emerged as important factors in T-ALL progression
and relapse. For example, CCR7, a known regulator of Tlymphocyte migration, is necessary and sufﬁcient to drive
inﬁltration of T-ALL cells into the CNS in a mouse model45
and inhibition of CXCR3, another lymphocyte migratory
factor, signiﬁcantly reduced leukemic inﬁltration into bone
marrow, spleen and CNS46. Whether PRL-3 expression
drives migration on its own or is associated with lymphocyte migratory signaling cascades is an area we are actively
investigating. Nonetheless, there is a strong precedent for
genes involved in migration, such as CCR7, CXCR3, and
now PRL-3, as having critical roles in T-ALL progression.
We have demonstrated that PRL-3 modulates the SRC
signaling pathway in T-ALL cell lines. Src activation has
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Fig. 6 The PRL inhibitor JMS-053 reduces Src pathway activation and inhibits T-ALL migration. a JMS-053 reduced cell viability in T-ALL cell
lines with high PRL-3 expression, evaluated by quantifying ATP production via Cell-Titer Glo, *p ≤ 0.001 or NS = not signiﬁcant, compared to DMSO.
b JMS-053 treatment (10 μM) for 2 h suppressed cell migration of T-ALL cells, **p < 0.001 compared to DMSO. For all, bars are the average of three
experiments, each done in triplicate, ± standard deviation. c JMS-053 (10 µM) treatment increased Src phosphorylation at tyrosine 527. Blots are
representative of at least three independent experiments. The numbers in the blot are relative expression normalized to total protein loaded. d Cell
migration capability of PRL-3 overexpressing cells was compared between groups treated with DMSO, Src inhibitor Su6656 (2.5 μM), JMS-053 (10 μM)
or in combination and showed no additive effects between Su6656 and JMS-053, NS = not signiﬁcant, ***p < 0.05.

been reported in many types of human cancer, with a
prominent role in regulating motility, migration, and
metastasis37,47,48. PRL-3 has been previously reported to
play a role in Src pathway activation in solid tumors and
benign human cell lines38,49. Our study expands the role
of PRL-3 in SRC signaling pathway modulation to include
Oncogenesis

T-ALL, suggesting that PRL-3 might be a central regulator of the Src signaling network across multiple cancer
types. However, our data showed that Src _Y527 is not a
direct target of PRL-3 in T-ALL. It is more likely that
PRL-3 affects CSK protein levels, which can directly
phosphorylate Src_Y527, yet the exact mechanism of SRC
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activation requires further investigation. Additionally, we
cannot exclude other possible PRL-3 effectors that could
also directly or indirectly affect Src_pY527. Our RPPA
analyses determined that the expression of other proteins
were affected by PRL-3, including Histone-H3, Chk2,
JNK, Hes1, Rictor, Axl, and Hif1-alpha, all of which play
known roles in tumor progression, and may represent
novel mechanisms by which PRL-3 promotes T-ALL.
In summary, our study expanded the oncogenic role of
PRL-3 to T-ALL using both in vitro and in vivo assays.
We found PRL-3 promotes T-ALL development and
onset in both zebraﬁsh and mouse xenograft models.
Importantly, we also found that chemical inhibition of
PRL-3 can inhibit cell growth and migration, suggesting
that PRL-3 is a feasible therapeutic target in T-ALL. Cellculture based assays revealed that PRL-3 modulates SRC
signaling in T-ALL to enhance migratory capability, with
no signiﬁcant effect on cell growth. Given that several
genes involved in T-cell migration promote CNS and
bone marrow relapse, further studies on the role of PRL-3
in CNS inﬁltration and relapse of T-ALL are necessary.
There is increasing interest in developing PRL-3 inhibitors for use in solid tumors; our study indicates that they
may be useful in T-ALL as well.

Materials and methods
Antibodies, DNA plasmids, and other reagents

Antibodies used in this study, including their manufacturer, catalog number, lot number, blocking buffer
used, and dilution factor are listed in Supplemental Table
4. The speciﬁcity of antibodies against PRL-1, 2, and 3
were validated against puriﬁed protein (Supplemental Fig.
8). The PRL inhibitor JMS-053 was kindly provided by Dr.
John S. Lazo, Elizabeth Sharlow, and Peter Wipf (University of Virginia, Charlottesville, VA, USA), and the Src
inhibitor, SU6656, was purchased from Sigma-Aldrich
(S9692, St. Louis, MO, USA).
Lentiviral packaging plasmids psPAX2 (Addgene 12260,
Watertown, MA, USA) and pMD2.G (Addgene 12259)
were from Didier Trono. pLenti PGK Puro DEST (w529-2)
(hereafter referred to as PGK) (Addgene 19068) and
pLenti PGK GFP Puro (w509-5) (Addgene 19070) were
from Eric Campeau & Paul Kaufman. Non-targeting
control pLKO shRNA lentivirus plasmid (MISSION,
SHC002, Sigma-Aldrich) was kindly provided by Tianyan
Gao and pLKO shRNAs targeting PRL-3 were purchased
from Sigma-Aldrich; target sequences are listed in Supplemental Table 5.
pENTR:PRL-3 (human) and pENTR:prl-3 (zebraﬁsh)
Gateway Entry constructs were made by PCR amplifying
PRL-3 and prl-3 from cDNA generated from human
T-ALL cells and 24 h post-fertilization zebraﬁsh embryos,
respectively. The PCR products were subcloned into the
pENTR-d-TOPO cloning vector (ThermoFisher K2400Oncogenesis
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20, Waltham, MA, USA). The Gateway compatible zebraﬁsh rag2 vector and generation of the rag2:Myc and
rag2:mCherry construct has been previously described34.
The PGK:PRL-3 and rag2:prl-3 constructs were generated
using the PGK destination vector and pENTR:PRL-3 or
the rag2 destination vector and pENTR:prl-3 along with
Gateway LR Clonase II enzyme mix, according to manufacturer’s protocol (ThermoFisher 11791020).
T-ALL cell lines and cell culture

All the human T-ALL cell lines used in the study were
authenticated by short tandem repeat (STR) DNA proﬁling and tested for mycoplasma contamination prior to
experimentation. Cells were grown in RPMI1640 (ThermoFisher 11875119) supplemented with 10% heatinactivated fetal bovine serum (Atlanta Biologicals,
S11150H, Lot M17161, Flowery Branch, GA, USA). Cells
were cultured at 37 °C in a humidiﬁed atmosphere with
5% CO2.
Western blot

Western blot analysis was performed using a stain-free
technology developed by BioRad, which allows use of total
protein as the loading control50,51. For all ﬁgures shown,
the bands of total protein ~50 kD in size are used to
represent the lane of total protein. An example of the
entire lane that is used in the normalization calculations is
shown in Supplemental Fig. 9.
Co-immunoprecipitation

Cells (~50 million) were lysed in Pierce IP lysis buffer
(Thermo 87788) supplemented with 1% Protease Inhibitor Cocktail (Sigma P8465). Total protein was incubated
with 80 μL Anti-Flag M2 magnetic beads (Sigma m8823)
on an orbital shaker overnight. After removing supernatant and washing the beads with PBS, the magnetic
beads were boiled with 50 μL SDS containing buffer to
elute the immunoprecipitants from the beads. Total cell
lysates and immunoprecipitants were used for western
blot analysis.
Primary human samples

Frozen isolated PBMCs from de-identiﬁed T-ALL
patients were kindly provided by Dr. Michelle Kelliher
(University of Massachusetts Medical School, Worcester,
MA, USA). PBMCs from healthy donors were purchased
from Precision for Medicine (Bethesda, MD, USA).
Microarray data analysis

The primary patient microarray datasets were accessed
through the Gene Expression Ominbus (GEO) at NCBI
(https://www.ncbi.nlm.nih.gov/geo), including GSE1315952,53
and GSE1461554,55. GSEA was done using GSEA 4.0.0. PRL3 expression levels, corresponding to Affymetrix probes
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209695_at and 206574_at were used for phenotypic labeling.
Enrichment was calculated using MSigDB collection C6,
oncogenic gene sets. Gene set enrichment was considered
signiﬁcant if it had a nominal p-value < 0.05.
Lentivirus packaging and T-ALL cells infection

For PRL-3 knock-down, lentivirus was produced in
293T cells using TransIT-LT1 (Mirus Bio MR2300,
Madison, WI, USA), according to the manufacturer’s
instructions using scrambled or shPRL-3 plasmids. For
T-ALL cell infection, 2.5 mL virus with 10 μg/mL polybrene (Thermo Fisher Scientiﬁc TR-1003-G) was added to
5 × 105 cells and centrifuged at 2250 rpm for 90 min.
Virus was washed out with PBS after 24 h, and cells were
selected in culture media with 5 μg/mL puromycin for
48 h before experiments.
To generate PRL-3-ovexpressing cell lines, 293T cells
were transfected with PGK:GFP with or without PGK:
PRL-3 or PGK:3xFLAG-PRL-3 as described above. T-ALL
cells were selected in medium with 5 μg/mL puromycin
(Jurkat) or 1 μg/mL puromycin (HBP-ALL) for one week
to produce stably expressing cell lines, then maintained in
media with puromycin thereafter.
In vitro cell-based assays

The CellTiter-Glo Luminescent Cell Viability Assay
(Promega, G7570, Madison, WI, USA) was used to measure
cell survival according to the manufacturer’s instructions. A
Synergy LX BioTek (Winooski, VT, USA) multi-mode plate
reader was used to read luminescent signal.
Migration assays were performed as previously described56. In experiments using JMS-053 or SU6656, cells
were pre-treated with JMS-053, SU6656, or DMSO control for 2 h before plating into the upper chamber. The
cells that migrated into the lower chamber were quantiﬁed by CellTiter-Glo Luminescent Cell Viability Assay.
Cell cycle was analyzed by quantifying 5′-ethynyl-2′deoxyuridine (EdU) uptake using ClickIT EdU Alexa
Fluor 647 (Thermo Fisher Scientiﬁc, C10424) according
to the manufacturer’s protocol. DAPI (0.1 μg/ml) (ThermoFisher 62248) was used to stain the DNA.
Apoptosis was quantiﬁed by staining cells with Annexin V
APC (ThermoFisher 88-8007-74) according to the manufacturers protocol, in the presence of DAPI (0.05 μg/ml)
RPPA assay and data processing

Reverse Phase Protein Array (RPPA) and data analysis
were performed by the RPPA Core Facility at MD
Anderson Cancer Center (Houston, TX, USA) as previously described57.
Zebraﬁsh T-ALL models

Use of zebraﬁsh was approved by the University of Kentucky’s Institutional Animal Care and Use Committee
Oncogenesis
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(IACUC), protocol 2015–2225. Microinjections of 15 ng/μL
rag2:Myc + 45 ng/μL rag2:mCherry or 15 ng/μL rag2:Myc +
15 ng/μL rag2:prl-3 + 30 ng/μL rag2:mCherry were used to
generate zebraﬁsh T-ALL in CG1 strain zebraﬁsh as previously described, and number of animals used in each group
were chosen based on previous experiments35,58. Zebraﬁsh
were monitored for leukemia onset and progression starting
at 21 days post-fertilization (dpf) and every 3 days onwards
by analyzing percent of the body expressing mCherrypositive leukemia cells using a Nikon ﬂuorescence-equipped
SMZ25 microscope. Circulating mCherry-positive T-ALL
was noted by examining the vessels within the tail vasculature. Animals were monitored until 90 dpf or until they had
to be sacriﬁced due to leukemia burden. Animals that died
before the end of the monitoring period without leukemia
progression outside the thymus were excluded.
Zebraﬁsh leukemias were harvested and May-Grunwald
Giemsa staining were performed as previously described
before imaging on a BioTek Lionheart FX microscope34,35. To assess gene expression, RNA was isolated
from the cells using Zymo Research Quick-RNA kit
(R1054, Irvine, CA, USA). Total RNA was reverse transcribed (BioRad iSCRIPT, 1708891) and real time PCR
performed using iTaq Universal SYBR Green Supermix
(Biorad, 1725120) with primer sequences available in
Supplemental Table 6. Data were normalized to ef1a
expression and fold change was calculated using the
2-ΔΔCq method.
Xenograft models in immune-compromised mice

Use of mice was approved by the University of Kentucky’s IACUC, protocol 2017–2754. Eight-week old
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice were
obtained from Jackson Laboratory (Bar Harbor, ME,
USA). Eight mice per group were used for experiments
based on pilot studies that utilized three mice per group.
The mice were randomized by placing into groups such
that the difference between average group weight is not
greater than 10%. Jurkat cells were infected with Scrambled shRNA or PRL-3 shRNA as described above. Two
days after virus infection, Jurkat cells were selected using
5 μg/ml puromycin for two days, stained with trypan blue,
and viable cells were FACS isolated. 106 live cells in
100 μL PBS were injected intravenously. Peripheral blood
samples (100–150 μL) were collected by submandibular
bleeding at 4, 6, and 8 weeks post-transplantation and
stained with human CD45 antibody according to Biolegend’s protocol and analyzed by ﬂow cytometry.
Statistical analysis

Results are shown as mean ± standard deviation. Sample
sizes and number of replicates were chosen based on pilot
experiments utilizing three samples per group, and
experiments were done unblinded. At least three
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biological replicates were performed in each experiment.
Statistical analyses were performed using GraphPad Prism
7 (San Diego, CA, USA), combining data from all samples
across all replicates. Two-tailed t-tests were performed to
compare two groups with similar distribution, and Analysis of Variance (ANOVA) with Tukey’s multiple comparisons was used to compare more than two groups.
Human microarray data were analyzed using two-sample
t-test and Wilcoxon rank sum tests, and survival curves
were analyzed using Log-rank tests. All bar graphs shown
are data pooled from ≥3 experiments.
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